source
- FDA greenlights Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia veraThe U.S. Food and Drug Administration has granted approval to rusfertide, a therapy developed jointly by Takeda Pharmaceutical and Protagonist Therapeutics. The drug, to be marketed under the name…
- Biotech Index Surges as IPOs and M&A Activity Accelerate in 2026The XBI biotech index, which had fallen to about $64 per share three years ago, has climbed back to near $170, almost doubling its value over the past year. Investor interest is reflected in a wav…